Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 13, 2025
Interleukin-34-Induced Arg1+ Macrophages Play a Key Role in Breast Cancer Brain Metastasis.
Journal: Cancer research communications
Published: October 15, 2025
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2025
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages.
Journal: bioRxiv : the preprint server for biology
Published: July 16, 2025
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer.
Journal: Scientific reports
Published: January 19, 2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 21, 2024
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Journal: Nature communications
Published: October 17, 2024
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2024
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis.
Journal: BMC nephrology
Published: August 14, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2024
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.
Journal: bioRxiv : the preprint server for biology
Published: November 14, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 04, 2023
Last Updated: 09/26/2026